The present study was evaluated the impact of Consciousness Energy Healing/Blessing Treatment (the Trivedi Effect®) on a novel test formulation in male Sprague Dawley (SD) rats. The animals were fed with Vitamin D3 Deficiency Diet (VDD) for the estimation of vitamin D3 metabolites such as 25-hydroxy cholecalciferol (25(OH) D3), and 1, 25-dihydroxy cholecalciferol (1, 25(OH)2 D3) in liver and serum samples; while cytochrome P450 enzymes (CYP24A and CYP27B) in liver homogenate. A novel proprietary test formulation was formulated including minerals (magnesium, zinc, copper, calcium, selenium, and iron), vitamins (ascorbic acid, pyridoxine HCl, alpha tocopherol, cyanocobalamin, and cholecalciferol), Panax ginseng extract, β-carotene, and cannabidiol isolate. The test formulation was divided into two parts; one part was defined as untreated test formulation, while the other parts of test formulation and three groups of the animals received Biofield Energy Healing Treatment by a renowned Biofield Energy Healer, Mr. Mahendra Kumar Trivedi. The expression of vitamin D3 metabolites like 25(OH) D3 level in liver homogenate was significantly (p≤0.001) increased by 184.83% in the Vitamin D Deficient (VDD) Diet + Biofield Energy Treatment per se to animals from day -15 (G6) group as compared to the VDD + untreated test formulation group (G4). Moreover, the level of 1, 25(OH)2 D3 was significantly increased by 18.28% and 32.83% in the G6 and VDD + Biofield Energy Treatment per se animals plus untreated test formulation (G9) groups, respectively as compared to the VDD + 0.5% CMC (G2) group. The expression of cytochrome P450 family 24 subfamily A member (CYP24A) in liver homogenate was significantly increased by 20.2% and 18.78% in the VDD + Biofield Energy Treated test formulation (G5) and VDD + Biofield Energy Treated test formulation from day -15 (G7) groups, respectively as compared to the G2 group. Additionally, the level of CYP27B expression was significantly increased by 12.45% and 13.78% in the G5 and VDD + Biofield Energy Treatment per se plus Biofield Energy Treated test formulation from day -15 (G8) groups, respectively as compared to the G2 group. Further, in serum the level of 25(OH) D3 was significantly (p≤0.001) increased by 7401.14%, 8976.1%, 10838.65%, and 9958.1% in the G5, G7, G8, and G9 groups, respectively as compared to the G2 group. Moreover, the level of 1, 25(OH)2 D3 was significantly (p≤0.001) increased by 186.26%, 167.99%, 130.54%, and 166.40% in the G5, G7, G8, and G9 groups, respectively as compared to the G2 group. Altogether, the Biofield Treated test formulation and Biofield Energy Treatment per se significantly increased the expression of vitamin D3 metabolites and mitochondrial enzyme functions. Thus, it could be helpful for the management of bone metabolic disorders, tumors, cardiovascular diseases, neuropsychiatric disorders, autoimmune diseases, and diabetes. Overall, the results showed the significant slowdown the disease progression and disease-related all other complications/symptoms in the preventive Biofield Energy Treatment group per se and/or Biofield Energy Treated Test formulation groups (viz. G6, G7, G8, and G9) compared with the disease control group.
